Gil Roth12.17.13
Phase I
ArGEN-X hits dose escalation goals . . . read more
Phase II
Aquinox begins COPD trial . . . read more
Asmacure advances lead lung compound . . . read more
Phase III
Amgen MAb reduces LDL-C . . . read more
BI drug hits endpoint in VTE trial . . . read more
Ipsen's Dysport posts positive results in spasticity trial . . . read more
RedHill begins dosing gastritis trial . . . read more
Sucampo, Takeda begin constipation trials . . . read more
Filings
Aethersys gets Orphan status in EU for stem cell GvHD therapy . . . read more
Launches
Amneal releases Nexium alternative . . . read more
ArGEN-X hits dose escalation goals . . . read more
Phase II
Aquinox begins COPD trial . . . read more
Asmacure advances lead lung compound . . . read more
Phase III
Amgen MAb reduces LDL-C . . . read more
BI drug hits endpoint in VTE trial . . . read more
Ipsen's Dysport posts positive results in spasticity trial . . . read more
RedHill begins dosing gastritis trial . . . read more
Sucampo, Takeda begin constipation trials . . . read more
Filings
Aethersys gets Orphan status in EU for stem cell GvHD therapy . . . read more
Launches
Amneal releases Nexium alternative . . . read more